Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of PepGNP-Covid19 Vaccine in Healthy Adults
NCT05113862Phase 1Completed
- Sponsor
- Gylden Pharma
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PepGNP-COVID19 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Gylden Pharma. Primary endpoints: Solicited local & systemic Adverse Events at 14 days, Unsolicited Adverse Events at 180 days and 2 more. Started Jan 2022; status: completed.
02
Drugs
PepGNP-COVID19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05113862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113862.